<DOC>
	<DOCNO>NCT01691040</DOCNO>
	<brief_summary>This study conduct determine safety , tolerability , efficacy NOX-H94 patient anemia chronic disease ( ACD ) . Furthermore , study intend provide data need correlate plasma concentration NOX-H94 efficacy choose appropriate dose dose schedule subsequent efficacy study . Some chronic disease , e.g . tumor , inflammation , renal disease , associate high hepcidin concentration blood . These hepcidin concentration cause reduction iron concentration blood subsequently impair formation red blood cell . Treatment NOX-H94 expect inhibit patho-mechanism bind inactivate hepcidin .</brief_summary>
	<brief_title>Efficacy NOX-H94 Anemia Chronic Disease Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Hepcidins</mesh_term>
	<criteria>Written inform consent Female male age &gt; 18 year Clinically significant anemia chronic disease ( ACD ) attribute histologically cytologically proven malignancy , either hematological solid tumor , grade stage : Hemoglobin ( Hb ) 7.0 g/dL 10 g/dL , Transferrin saturation ( TSAT ) &lt; 50 % , Serum iron &lt; 50 µg/dL ( SI : &lt; 9.0 µmol/L ) , AND Ferritin &gt; 30 ng/mL ( SI : &gt; 30 µg/L ) Previous treatment systemic anticancer therapy / regimen Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Estimated life expectancy ≥12 week Men must agree follow effective contraception method treatment 3 month completion treatment . Women childbearing potential must agree use two form effective contraception treatment 3 month completion treatment . Inability personally provide write informed consent understand collaborate throughout study History pure red cell aplasia , thalassemia major sickle cell disease History anemia unrelated cancer &lt; 10 g/dL within 6 month prior screen Uncorrected iron deficiency Regular need blood transfusion interval &lt; 6 week Acute myeloid leukemia Known suspect chronic bleeding Tumor gastrointestinal involvement without negative test fecal occult blood Suspected known history hemochromatosis Known infection human immunodeficiency virus , hepatitis B , hepatitis C Impaired liver function bilirubin ≥2.0 mg/dL ( 26 μmol/L ) , AST ALT ≥2 time upper limit History risk significant hepatic disease , e.g . chronic alcohol abuse , hepatic steatosis , hepatic cirrhosis , organ transplantation Severe renal impairment : estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min ( CockcroftGault ) Known central nervous system malignancy metastasis Significant cardiac disease ( e.g . uncontrolled hypertension : systolic blood pressure [ BP ] &gt; 150 mmHg diastolic BP &gt; 100 mmHg ; myocardial infarction unstable angina pectoris ) within 6 month prior screen Positive pregnancy test ( serum ßhCG screening , urine pregnancy test prior first treatment ) lactation Previous participation study treatment investigational agent &lt; 21 day prior treatment start Hemolysis bleeding &gt; 500 mL ( measure estimate ) within 6 week prior treatment start Treatment erythropoiesisstimulating agent ( ESAs ) red blood cell ( RBC ) transfusion &lt; 21 day prior treatment start Cytotoxic antitumor treatment &lt; 21 day prior treatment start plan anticipated study period ( within 3 month treatment start randomization ) . Maintenance therapy permit throughout study ( e.g . lenalidomide , interferon )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hepcidin</keyword>
	<keyword>Iron</keyword>
	<keyword>Anemia Chronic Disease</keyword>
	<keyword>Anemia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Iron restriction</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>CLL</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Hodgkin</keyword>
	<keyword>anti-hepcidin</keyword>
</DOC>